RT Journal Article
T1 Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study.
A1 Escamilla-Gomez, Virginia
A1 Garcia-Gutierrez, Valentin
A1 Lopez-Corral, Lucia
A1 Garcia-Cadenas, Irene
A1 Perez-Martinez, Ariadna
A1 Marquez-Malaver, Francisco J
A1 Caballero-Velazquez, Teresa
A1 Gonzalez-Sierra, Pedro A
A1 Viguria-Alegria, Maria C
A1 Parra-Salinas, Ingrid M
A1 Calderon-Cabrera, Cristina
A1 Gonzalez-Vicent, Marta
A1 Rodriguez-Torres, Nancy
A1 Parody-Porras, Rocio
A1 Ferra-Coll, Christelle
A1 Orti, Guillermo
A1 Valcarcel-Ferreiras, David
A1 De-la-Camara-LLanza, Rafael
A1 Moles, Paula
A1 Velazquez-Kennedy, Kyra
A1 João-Mende, Maria
A1 Caballero-Barrigon, Dolores
A1 Perez, Estefania
A1 Martino-Bofarull, Rodrigo
A1 Saavedra-Gerosa, Silvanna
A1 Sierra, Jorge
A1 Poch, Marc
A1 Zudaire-Ripa, Maria T
A1 Diaz-Perez, Miguel A
A1 Molina-Angulo, Blanca
A1 Sanchez-Ortega, Isabel
A1 Sanz-Caballer, Jaime
A1 Montoro-Gomez, Juan
A1 Espigado-Tocino, Ildefonso
A1 Perez-Simon, Jose A
K1 Drug development
K1 Molecularly targeted therapy
K1 Acute Disease
K1 Hematopoietic Stem Cell Transplantation
K1 Pyrazoles
AB Graft-versus-host disease is the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. First-line treatment is based on the use of high doses of corticosteroids. Unfortunately, second-line treatment for both acute and chronic graft-versus-host disease, remains a challenge. Ruxolitinib has been shown as an effective and safe treatment option for these patients. Seventy-nine patients received ruxolitinib and were evaluated in this retrospective and multicenter study. Twenty-three patients received ruxolitinib for refractory acute graft-versus-host disease after a median of 3 (range 1-5) previous lines of therapy. Overall response rate was 69.5% (16/23) which was obtained after a median of 2 weeks of treatment, and 21.7% (5/23) reached complete remission. Fifty-six patients were evaluated for refractory chronic graft-versus-host disease. The median number of previous lines of therapy was 3 (range 1-10). Overall response rate was 57.1% (32/56) with 3.5% (2/56) obtaining complete remission after a median of 4 weeks. Tapering of corticosteroids was possible in both acute (17/23, 73%) and chronic graft-versus-host disease (32/56, 57.1%) groups. Overall survival was 47% (CI: 23-67%) at 6 months for patients with aGVHD (62 vs 28% in responders vs non-responders) and 81% (CI: 63-89%) at 1 year for patients with cGVHD (83 vs 76% in responders vs non-responders). Ruxolitinib in the real life setting is an effective and safe treatment option for GVHD, with an ORR of 69.5% and 57.1% for refractory acute and chronic graft-versus-host disease, respectively, in heavily pretreated patients.
PB Nature Publishing Group
YR 2020
FD 2020-03
LK http://hdl.handle.net/10668/14653
UL http://hdl.handle.net/10668/14653
LA en
NO Escamilla Gómez V, García-Gutiérrez V, López Corral L, García Cadenas I, Pérez Martínez A, Márquez Malaver FJ, et al.  Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study. Bone Marrow Transplant. 2020 Mar;55(3):641-648.
DS RISalud
RD Aug 24, 2025